GCC19CART for Colorectal Cancer

(CARABiNER Trial)

This trial tests a new treatment called GCC19CART, a type of cell therapy, for individuals with metastatic colorectal cancer that has returned or resisted other treatments. The primary goal is to assess the safety and effectiveness of this treatment. Participants should have colorectal cancer that has spread, a specific positive result on an immunohistochemistry test, and limited liver disease. This trial targets those who have tried other treatments, such as chemotherapy and biological therapies, but require new options. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this new therapy.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that GCC19CART was safe and well-tolerated in earlier studies with patients who have advanced colorectal cancer previously treated multiple times. Most patients experienced mild side effects, such as cytokine release syndrome, where the immune system becomes very active. About 90% of these cases were mild, with only around 5% experiencing more serious symptoms. Diarrhea was another common side effect, affecting a similar number of patients. Overall, these findings suggest that GCC19CART is safe enough for those considering participation in a clinical trial.¹²³⁴⁵

Unlike the standard of care for colorectal cancer, which typically involves chemotherapy, radiation, and surgery, GCC19CART is a novel approach that uses genetically modified T-cells specifically engineered to target cancer cells. This treatment stands out because it uses chimeric antigen receptor (CAR) T-cell therapy, which is designed to enhance the immune system's ability to fight cancer by recognizing and attacking cancer cells more effectively. Researchers are excited about GCC19CART because it offers a personalized treatment option that could potentially provide better outcomes for patients, particularly those who do not respond well to conventional therapies.

Research has shown that GCC19CART could be a promising treatment for advanced colorectal cancer that hasn't responded to other therapies. In this trial, all participants will receive a single infusion of GCC19CART, with the dose depending on their assigned dose level. Studies have found this therapy effective; one study showed a 56% overall response rate, meaning more than half of the patients experienced positive results. Another study reported tumor shrinkage in 50% of cases for patients receiving a higher dose. The treatment also proved durable, with patients experiencing a period without cancer progression ranging from 5 to 7.8 months. Overall, GCC19CART has been safe and manageable for patients who have tried several other treatments.¹²⁴⁶⁷